Immunotherapy Drugs Market size was valued at USD 290.22 billion in 2024 and is set to exceed USD 1.82 trillion by 2037, registering over 15.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of immunotherapy drugs is estimated at USD 327.72 billion.
Increasing prevalence of targeted diseases worldwide, along with the increasing adoption of immunotherapy drugs over conventional treatments, and the rising demand for oncology biosimilars, and monoclonal antibodies are some of the major factors anticipated to drive the market growth. Further, growing advancements in cancer research and immunotherapy treatment, such as cellular immunotherapy, melanoma immunotherapy, immunotherapy drugs for lung cancer, and others, and the increasing cancer immunotherapy drugs approved by the United States Food and Drug Administration (FDA) are further anticipated to drive the growth of the global immunotherapy drugs market in the coming years.
The global immunotherapy drugs market is thriving on account of the growing need for the cure and treatment of chronic and targeted diseases globally, along with the increasing favorable initiatives of the government of nations to enhance research and development in the field of various targeted diseases, and the growing investments of the pharmaceutical companies for the development of advanced oncology biosimilars and other immunotherapy drugs. Until 2020, the National Cancer Institute (NCI) of the National Institute of Health (NIH), U.S. Department of Health and Human Sciences, invested over USD 1 billion in funding to support more than 240 research projects across around 70 cancer science initiatives. The initiatives that had been established to address the goals of the project is mentioned below:
Few of the initiatives that supported on expanding the benefits of immunotherapy included the development of Immuno-Oncology Translational Network (IOTN) for adults, Pancreatic Cancer Microenvironment Network (PaCMEN) for finding immunotherapies for pancreatic tumor, and the development of Pediatric Immunotherapy Discovery and Development Network (PI-DDN) among others.
Growth Drivers
Growing Adoption of Targeted Therapies for Treating Cancer
Targeted therapy is referred to the process of treating cancer by using drugs to target specific proteins and genes that are involved in the growth and survival of the cancer cells. The therapy is either used individually or with chemotherapy and other treatments. Over the past few years, with increasing research and advancements in drugs developed for prevention and cure of cancer diseases, the U.S. FDA has approved several targeted therapies for treating different forms of cancer. There are several types of targeted therapy that include angiogenesis inhibitors, immunotherapies, and apoptosis inducers among others, out of which, the most common ones are monoclonal antibodies type of immunotherapy and small-molecule drugs, such as angiogenesis inhibitors. Backed by the growing prevalence of cancer diseases globally, and the advancements in research, healthcare practitioners are increasingly adopting targeted therapies for treating cancer, which is anticipated to drive the market growth in the coming years.
Restraints
High Cost Associated with Immunotherapy Treatment
The treatment of cancer using immunotherapy drugs is significantly high and is not affordable by several low- and middle-income groups. Moreover, lack of proper healthcare infrastructure in several nations around the globe is also anticipated to hamper the adoption of immunotherapy drugs, and in turn lower the market growth during the forecast period.
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
15.2% |
|
Base Year Market Size (2024) |
USD 290.22 billion |
|
Forecast Year Market Size (2037) |
USD 1.82 trillion |
|
Regional Scope |
|
The global immunotherapy drugs market is segmented by therapy area into cancer, infectious diseases, inflammatory & autoimmune diseases, and others. Among these segments, the cancer segment is anticipated to register the largest market share by the end of 2021. The growth of the segment can be attributed to the growing prevalence of cancer diseases globally, and the increasing need for prevention and cure of such chronic diseases, backed by the rising burden and the risks associated with the disease. According to the statistics by the World Health Organization (WHO), in the year 2018, around 9.6 million deaths was caused due to cancer, a disease which is also the second leading cause of death around the world. Moreover, increasing research and advancements in immune-oncology, along with the growing research for immunotherapy cure for stage-4 cancer, are some of the additional factors anticipated to drive the growth of the segment during the forecast period.
Our in-depth analysis of the global market includes the following segments
|
By Type |
|
|
By Therapy Area |
|
North America Market Statistics
On the basis of regional analysis, the global immunotherapy drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa regions. North America industry is predicted to account for largest revenue share by 2037, on the back of presence of several key players, along with growing number of new cancer cases registered every year in the region.
June 29, 2020: The United States Food and Drug Administration announced the approval of Keytruda (pembrolizumab), an immunotherapy (anti-PD-1 therapy) drug developed by Merck & Co., Inc., for the first-line treatment of mismatch repair deficient (dMMR) or unresectable or metastatic microsatellite instability-high (MSI-H) colorectal cancer.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?